Biopharmaceutical company Poolbeg Pharma (AIM: POLB) (OTCQB: POLBF) announced on Wednesday that it has been granted a Notice of Allowance from the US Patent Office for its Immunomodulator II patent application, enhancing its intellectual property portfolio. The notice signifies an impending formal grant of a patent.
The approved claims cover a class of drugs, including POLB 001, targeting hypercytokinaemia (cytokine storm) treatment and prevention post-immune response activation. POLB 001, a Phase II-ready p38 MAP kinase inhibitor, shows promise across various disease areas, particularly in severe influenza and cancer immunotherapies.
Poolbeg Pharma is actively expanding its patent portfolio, focusing on p38 MAP kinase inhibitors for severe influenza and POLB 001 for hypercytokinaemia treatment. Additional patent filings aim to broaden coverage, especially in cancer immunotherapies, boosting the appeal of POLB 001 to potential Pharma partners.
Committed to addressing diseases with high unmet medical needs, Poolbeg Pharma targets rare and orphan diseases. Led by a seasoned team, including former Amryt Pharma plc executives, Poolbeg aims to replicate past successes, driving value creation and near-term revenues.
The company's clinical programmes encompass cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions like obesity. Leveraging cost-effective development approaches and AI-led infectious disease programmes, Poolbeg accelerates drug development, offering greater commercial appeal and partnership opportunities.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva